AG-CN2-0476-M250250 mgCHF 60.00
AG-CN2-0476-G0011 gCHF 120.00
|Synonyms||Betulinol; Trochol; NSC 4644|
|Merck Index||14: 1198|
|Source/Host Chemicals||Isolated from Betulaceae family tree bark.|
|Purity Chemicals||≥98% (NMR)|
|Solubility||Soluble in DMSO, DMF or ethanol.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
|Handling Advice||Protect from light.|
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
- Specific SREBPs (sterol regulatory element-binding proteins) inhibitor. Inhibits ER-Golgi translocation of SREBPs through binding to SCAP in an INSIG-dependent manner.
- Improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Lowers cholesterol levels through inhibition of SREBP-2 activation. Reduces weight gain and adipose tissue size in vivo. Increases oxygen consumption and energy expenditure. Increases UCP1/2 levels in brown adipose tissue (BAT) after cold stimulation.
- Anticancer compound. Apoptosis inducer. DNA topoisomerase II inhibitor.
- Anti-inflammatory compound. Shown to inhibit LPS-induced NO production through the TLR4/NF-κB signaling pathway.
- Antiviral compound.
- Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity: S. Wada, et al.; J. Nat. Prod. 64, 1545 (2001)
- The synergistic effects of betulin with acyclovir against herpes simplex viruses: Y. Gong, et al.; Antiviral Res. 64, 127 (2004)
- Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques: J.J. Tang, et al.; Cell Metab. 13, 44 (2011)
- A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products: J.R. Krycer, et al.; Biochem. J. 446, 191 (2012)
- Targeting SREBPs for treatment of the metabolic syndrome: S.M. Soyal, et al.; Trends Pharmacol. Sci. 36, 406 (2015)
- Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells: N.H. Yim, et al.; Oncol. Rep. 34, 1058 (2015)
- Comprehensive review on betulin as a potent anticancer agent: S.K. Krol, et al.; Biomed. Res. Int. 2015 (Review)
- Betulin derivatives effectively suppress inflammation in vitro and in vivo: M. Laavola, et al.; J. Nat. Prod. 79, 274 (2016)
- Betulin attenuates kidney injury in septic rats through inhibiting TLR4/NF-κB signaling pathway: H. Zhao, et al.; Life Sci. 144, 185 (2016)